The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Effect of Cholesterol-Lowering and Antioxidant Therapy on Endothelium-Dependent Coronary Vasomotion
Abstract
BACKGROUND: Patients with coronary artery disease and abnormalities of serum lipids often have endothelial vasodilator dysfunction, which may contribute to ischemic cardiac events. Whether cholesterol-lowering or antioxidant therapy can restore endothelium-dependent coronary vasodilation is unknown. METHODS: We randomly assigned 49 patients (mean serum cholesterol level, 209 +/- 33 mg per deciliter [5.40 +/- 0.85 mmol per liter]) to receive one of three treatments: an American Heart Association Step 1 diet (the diet group, 11 patients); lovastatin and cholestyramine (the low-density lipoprotein [LDL]-lowering group, 21 patients); or lovastatin and probucol (the LDL-lowering-antioxidant group, 17 patients). Endothelium-dependent coronary-artery vasomotion in response to an intracoronary infusion of acetylcholine (10(-8) to 10(-6) M) was assessed at base line and after one year of therapy. Vasoconstrictor responses to these doses of acetylcholine are considered to be abnormal. RESULTS: Treatment resulted in significant reductions in LDL cholesterol levels of 41 +/- 22 percent in the LDL-lowering-antioxidant group and 38 +/- 20 percent in the LDL-lowering group (P < 0.001 vs. the diet group). The maximal changes in coronary-artery diameter with acetylcholine at base line and at follow-up were -19 and -2 percent, respectively, in the LDL-lowering-antioxidant group, -15 and -6 percent in the LDL-lowering group, and -14 and -19 percent in the diet group (P < 0.01 for the LDL-lowering-antioxidant group vs. the diet group; P = 0.08 for the LDL-lowering group vs. the diet group). (The negative numbers indicate vasoconstriction). Thus, the greatest improvement in the vasoconstrictor response was seen in the LDL-lowering-antioxidant group. CONCLUSIONS: The improvement in endothelium-dependent vasomotion with cholesterol-lowering and antioxidant therapy may have important implications for the activity of myocardial ischemia and may explain in part the reduced incidence of adverse coronary events that is known to result from cholesterol-lowering therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary Arteries
Ludmer, P. L., Selwyn, A. P., Shook, T. L., Wayne, R. R., Mudge, G. H., Alexander, R. W., & Ganz, P. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610233151702 · Cited by 2,425
Self-citationBrown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart Disease: The Framingham Study
KANNEL, W. B., CASTELLI, W. P., GORDON, T., & MCNAMARA, P. M. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,057
Hypercholesterolemia increases endothelial superoxide anion production.
Ohara, Y., Peterson, T. E., & Harrison, D. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116491 · Cited by 1,765
Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.
Vita, J. A., Treasure, C. B., Nabel, E. G., McLenachan, J. M., Fish, R. D., Yeung, A. C., Vekshtein, V. I., Selwyn, A. P., & Ganz, P. (1990) · Circulation · doi:10.1161/01.cir.81.2.491 · Cited by 1,173
Self-citationKugiyama, K., Kerns, S. A., Morrisett, J. D., Roberts, R., & Henry, P. D. (1990) · Nature · doi:10.1038/344160a0 · Cited by 858
Brown, B. G., Zhao, X. Q., Sacco, D. E., & Albers, J. J. (1993) · Circulation · doi:10.1161/01.cir.87.6.1781 · Cited by 821
(1982) · JAMA · doi:10.1001/jama.248.12.1465 · Cited by 650
Probucol inhibits oxidative modification of low density lipoprotein.
Parthasarathy, S., Young, S. G., Witztum, J. L., Pittman, R. C., & Steinberg, D. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112349 · Cited by 618
The Effect of Atherosclerosis on the Vasomotor Response of Coronary Arteries to Mental Stress
Yeung, A. C., Vekshtein, V. I., Krantz, D. S., Vita, J. A., Ryan, T. J., Ganz, P., & Selwyn, A. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111283252205 · Cited by 599
Self-citationLeung, W.-H., Lau, C.-P., & Wong, C.-K. (1993) · The Lancet · doi:10.1016/0140-6736(93)90634-s · Cited by 451
Antioxidants and atherosclerosis. A current assessment.
Steinberg, D. (1991) · Circulation · doi:10.1161/01.cir.84.3.1420 · Cited by 392
Gage, J. E., Hess, O. M., Murakami, T., Ritter, M., Grimm, J., & Krayenbuehl, H. P. (1986) · Circulation · doi:10.1161/01.cir.73.5.865 · Cited by 369
Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis.
Harrison, D. G., Armstrong, M. L., Freiman, P. C., & Heistad, D. D. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113276 · Cited by 352
Simon, B. C., Cunningham, L. D., & Cohen, R. A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114718 · Cited by 309
Graham, A., Hogg, N., Kalyanaraman, B., O'Leary, V., Darley-Usmar, V., & Moncada, S. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80269-z · Cited by 278
Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment.
Osborne, J. A., Lento, P. H., Siegfried, M. R., Stahl, G. L., Fusman, B., & Lefer, A. M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113905 · Cited by 156
Mangin, E., Kugiyama, K., Nguy, J. H., Kerns, S. A., & Henry, P. D. (1993) · Circulation Research · doi:10.1161/01.res.72.1.161 · Cited by 155
Seiler, C. A., Hess, O. M., Buechi, M., Suter, T., & Krayenbuehl, H. P. (1993) · Circulation · doi:10.1161/01.cir.88.5.2139 · Cited by 142
Functional improvement precedes structural regression of atherosclerosis.
Benzuly, K. H., Padgett, R. C., Kaul, S., Piegors, D. J., Armstrong, M. L., & Heistad, D. D. (1994) · Circulation · doi:10.1161/01.cir.89.4.1810 · Cited by 106
Preservation of Endothelium-Dependent Relaxation in Atherosclerotic Rabbit Aorta by Probucol
Simon, B. C., Haudenschild, C. C., Cohen, R. A., & Palacino, J. J. (1993) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199306000-00007 · Cited by 59
Plane, F., Jacobs, M., McManus, D., & Bruckdorfer, K. R. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90041-r · Cited by 44
In vitro studies on the distribution of probucol among human plasma lipoproteins.
Urien, S., Riant, P., Albengres, E., et al. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15104-3 · Cited by 41
Cited by
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Endothelial Function and Dysfunction: Testing and Clinical Relevance
Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007) · Circulation · doi:10.1161/circulationaha.106.652859 · Cited by 2,710
Role of Oxidative Modifications in Atherosclerosis
Stocker, R., & Keaney, J. F. (2004) · Physiological Reviews · doi:10.1152/physrev.00047.2003 · Cited by 2,624
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,585
Metadata
- Authors
- Anderson, T. J., Meredith, I. T., Yeung, A. C., Frei, B., Selwyn, A. P., & Ganz, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-02-23
- Volume
- 332
- Issue
- 8
- Pages
- 488-493
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2315618879
- Cited by
- 1,109
- References
- 26
- FWCI
- 54.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.